Vanguard Group Inc Idera Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.23 - $0.43 $214 - $400	932 Added 0.07%	1,267,766 $443,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.53 $23,208 - $32,370	-61,076 Reduced 4.6%	1,266,834 $474,000
Q2 2022 Aug 12, 2022	BUY	$0.32 - $0.74 $64 - $148	200 Added 0.02%	1,327,910 $609,000
Q1 2022 May 13, 2022	SELL	$0.41 - $0.7 $102,068 - $174,263	-248,948 Reduced 15.79%	1,327,710 $664,000
Q4 2021 Feb 14, 2022	BUY	$0.53 - $1.03 $53,716 - $104,391	101,351 Added 6.87%	1,576,658 $899,000
Q3 2021 Nov 12, 2021	SELL	$1.0 - $1.18 $1,800 - $2,124	-1,800 Reduced 0.12%	1,475,307 $1.52 Million
Q2 2021 Aug 13, 2021	BUY	$1.01 - $1.58 $1.49 Million - $2.33 Million	1,477,107 New	1,477,107 $1.77 Million

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.